Rev. OFIL 2017, 27;1:11-17
Fecha de recepción: 07/07/2016 – Fecha de aceptación: 25/08/2016
____
Álvarez Martín T1, Ferrando Piqueres R2, Mendoza Aguilera M3, Borrego Izquierdo Y4, Pascual Marmaneu O1,
Bellés Medall MD2
1 Graduada/o en Farmacia. Farmacéutico Interno Residente. Servicio de Farmacia.
Hospital General Universitario de Castellón. Castellón (España)
2 Doctor en Farmacia. Facultativo Especialista en Farmacia Hospitalaria. Servicio de Farmacia.
Hospital General Universitario de Castellón. Castellón (España)
3 Licenciada en Farmacia. Farmacéutico Interno Residente. Servicio de Farmacia.
Hospital General Universitario de Castellón. Castellón (España)
4 Facultativo Especialista en Farmacia Hospitalaria. Servicio de Farmacia.
Hospital Universitario Nuestra Señora de Valme. Sevilla (España)
____
SUMMARY
Objective: To research the comorbidities of older HIV infected patients and type of concomitant medication. To identify and analyse clinically relevant interactions.
Methods: Single-centre retrospective study from January to June 2015. Patients over 55 years of age with antiretroviral therapy (ART) were included. The following variables were collected: age, sex, comorbidities, ART, concomitant medication, number and type of interaction, viral load and CD4. Micromedex and www.hiv-druginteractions.org website were consulted for the interactions evaluation. Data analysis was performed with the SPSS19.0 statistical package for Windows.
Results: 60 patients older than 55 years with active ART were included. 93% had comorbidities: gastrointestinal disorders (33%), hypercholesterolemia (28%), hypertension (27%) and diabetes (22%). 70% of the patients had treatment associated with ART: lipid-lowering (35%), antihypertensive (33%), psychiatric medication (27%). A total of 83 relevant interactions were recorded. Significant differences were observed in the interactions frequency, being higher in patients with 5 of more non-antiretroviral drugs. Significant differences were also found in patients who used integrase inhibitors (II) having a lower percentage of interactions (p=0,001), compared to those using non-nucleoside reverse transcriptase inhibitors (NNRTI) where the percentage was higher (p<0,001).
Conclusions: Comorbidities and drugs associated with ART were similar to those described in the literature. Co-medication increases the number of relevant interactions, being these more likely in regimens that include NNRTI and protease inhibitors and less on those using an II.
Key Words: Antiretroviral treatment, drug interactions, comorbidities, aging, HIV.
____
Download PDF: Polifarmacia y riesgo de interacciones farmacológicas en pacientes adultos con infección VIH